


Aradigm[®]


*A public benefit corporation promoting access
and affordability to cell and gene therapy*

May ♦ 2026



Medical breakthroughs are emerging quickly, but our healthcare system *isn't built to deliver them.*

Aradigm ensures sustainable access to transformative, high cost therapies through clinical, technology and financial infrastructure.



As high-prevalence treatments come to market, CGT coverage will increasingly press the system

3,000

CGTs in the pipeline


1M

Eligible patients for increasingly common conditions

\$3M+

Cost of just
1 gene therapy claim

Expected CGT Drug & Care Spend (PMPM)



Our system is not built to support access to cell and gene therapies, limiting access of life changing drugs

PURCHASERS

At prices upwards of \$4M/treatment, **payers and employers have limited tools to manage spend**, for a category they want to cover


PROVIDERS

Providers have **unpredictable volume of patients**, and lack the cash flow to support development of care delivery infrastructure


MANUFACTURERS

Coverage guidelines are slow to evolve with drug innovation, and **volatility has driven restrictive coverage and UM approaches**


Aradigm is a **fully carved-out required benefit** — connecting employers, health plans, manufacturers, and providers to creating sustainable access for CGT




Aradigm's market traction & progress



We **navigate patients** to the right provider — with **comprehensive coverage** for patients, and **improved payment** terms for providers



Our network model creates predictability across volume and payment for providers, helping them deepen program investment and expand access



Understanding our formulary

In 2026, we are targeting a smaller therapeutic coverage, with a planned expansion to all FDA approved therapies in 2027.

Therapy Class	Product	Aradigm Covered
CAR-T	Abecma, Carvykti, Yescarta, Breyanzi, Kymriah	✓
Sickle Cell	Casgevy, Lyfgenia	✓
Hemophilia	Hemgenix, Roctavian	✓
SMA	Zolgensma	✓
DMD	Elevidys	✓

How we select our preferred providers

NETWORK REQUIREMENTS

01 Rigorous clinical & institutional standards

Demonstrated CGT administration experience and evidence of appropriate prescribing

02 Timely access to care

Infrastructure to meet time-to-treatment benchmarks and regional patient demand

03 Data sharing & outcomes reporting

Ongoing performance monitoring with structured reporting obligations to Aradigm

04 Care coordination & navigation

Close alignment across referral, treatment, and post-care pathways

05 Standardized, predictable rate structure

Aligned rates that are competitive, transparent, and sustainable for all parties

PROVIDER TRACKS

ESTABLISHED PROGRAMS

Immediate participation and regional anchors

- Demonstrated CAR-T / gene therapy experience
- Evidence of high-quality outcomes
- Infrastructure for timely patient access

EMERGING & COMMUNITY PROGRAMS

Developmental COEs with structured progression

- Strong safety record in adjacent therapies
- Institutional commitment to CGT development
- Defined roadmap toward full program status

If you are interested in learning more, please reach out.

EVALUATION



Organizational Evaluation

Meet with organization to evaluate program fit



Contracts & rate proposal

Rate sheet shared by Aradigm

CONTRACTING PROCESS



Managed care review

Internal review of proposal terms



Legal & finance sign-off

Approvals from key departments



Clinical team review & sign-off

Clinical alignment and final approval

Thank You

